Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial - Cabanillas, M E; de Souza, J A; Geyer, S (J Clin Oncol, 2017)
et al.